Alembic Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Alembic Pharmaceuticals Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Alembic Pharmaceuticals Ltd.
Rating: 4
Author: Deven Choksey

Keep track of all breaking news and updates on Alembic Pharmaceuticals Ltd. from all sources in a single place.

Alembic Pharmaceuticals Ltd.

29 Aug 2025

955.75

1.25%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find attached herewith the Intimation under Regulation 30 of SEBI LODR Regulations, 2015- Analysts / Investor Meet

pdf

Alembic Pharmaceuticals Ltd.

19 Aug 2025

955.75

1.25%

Alembic Pharma shares rise 2% on pulmonary hypertension drug approval

Business Standard

Alembic Pharma shares rose 2.3 per cent on Tuesday, after the company received US Food & Drug Administration (USFDA) final approval for its Abbreviated New Drug Application (ANDA) Macitentan Tablets

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

19 Aug 2025

955.75

1.25%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg.

pdf

Alembic Pharmaceuticals Ltd.

18 Aug 2025

955.75

1.25%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Intimation Of One On One Investor Meet

BSE India

As attached.

pdf

Alembic Pharmaceuticals Ltd.

18 Aug 2025

955.75

1.25%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Analysts / Investors Meeting

pdf

Alembic Pharmaceuticals Ltd.

18 Aug 2025

955.75

1.25%

Alembic gets USFDA's approval for generic acne drug Tretinoin Cream

Business Standard

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic medication to treat acne vulgaris in the US market. The company has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Tretinoin Cream USP (0.025 per cent), the drug maker said in a statement. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Retin-A Cream, 0.025 pr cent, of Bausch Health US, LLC, it added. Tretinoin cream is indicated for topical application in the treatment of acne vulgaris. According to IQVIA, Tretinoin cream USP, 0.025 per cent, has an estimated market size of USD 94 million for the twelve months ending June 2025. Shares of the company were trading 1.03 per cent up at Rs 968.10 apiece on BSE.

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 955.5

Alembic Pharmaceuticals Ltd.

15 Aug 2025

955.75

1.25%

Company Update

Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Alembic Pharmaceuticals Limited announces USFDA final approval for Tretinoin Cream USP, 0.025%.

pdf

Alembic Pharmaceuticals Ltd.

12 Aug 2025

955.75

1.25%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.